Informação sobre produto
Taselisib is a small-molecule inhibitor of phosphatidylinositol 3-kinase (PI3K) and PI3K-related protein kinases. Taselisib is being investigated as a potential treatment for multiple myeloma, chronic lymphocytic leukemia, and other cancers. Taselisib is an orally available, potent, selective, and ATP competitive inhibitor of PI3K isoforms p110α and p110β. It has been shown to have antiproliferative effects in preclinical models of multiple myeloma, chronic lymphocytic leukemia, solid tumors, and hematopoietic stem cells. It also has anti-inflammatory properties that may be due to its inhibition of the production of proinflammatory cytokines such as tumor necrosis factor-α (TNFα), interleukin 1β (IL1β), IL6, IL8 and IL10.
Propriedades químicas
Consulta técnica sobre: 3D-BGC30530 1-Isopropyl-3-methyl-1H-1,2,4-triazole
Se desejar solicitar um orçamento ou fazer uma encomenda, por favor, adicione os produtos ao seu carrinho e depois solicite um orçamento ou encomenda a partir do carrinho. É mais rápido, mais barato e poderá beneficiar-se dos descontos e outras vantagens disponíveis.
